^
Association details:
| Biomarker: | IDH2 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | ocifisertib (CFI-400945) (PLK4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS
Published date:
11/04/2020
Excerpt:
Patient characteristics....somatic mutations...IDH2 mutation....Six patients were evaluable for disease response...3 pts (50%) had stable disease (with one patient having a 78% reduction in marrow blast count)....Single agent CFI-400945 has activity in patients with poor risk AML.
DOI:
https://doi.org/10.1182/blood-2020-138822
